CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L8019 - Common Stock
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
CYCC stock results show that Cyclacel Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclacel Pharmaceuticals (NASDAQ:CYCC) just reported results for the fourth qua...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – ...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma...
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Cyclacel Pharmaceuticals files to sell 411K shares of common stock (NASDAQ:CYCC)
Cyclacel Pharmaceuticals files a prospectus for the proposed sale of 411,969 shares of their common stock, but it is not an offer to sell these securities.
RKLB Stock Alert: The $500 Million Reason Rocket Lab Is Moving Today
Rocket Lab stock is on the move Tuesday as investors in RKLB react to a new $515 million contract with Space Development Agency.
Unity Layoffs 2024: What to Know About the Latest U Job Cuts
Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business.
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!
CYCC regains compliance with Nasdaq (NASDAQ:CYCC)
Cyclacel Pharmaceuticals regains compliance with minimum bid price requirement as per Nasdaq notification letter on January 4, 2024.
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!